Qian Jing, Zhao Xiaoping, Wang Weiting, Zhang Shujing, Hong Zhuping, Chen Xiaoling, Zhao Zhuanyou, Hao Chunhua, Wang Chenchen, Lu Shihai, Zhao Buchang, Wang Yi
Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
College of Preclinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Front Pharmacol. 2018 Mar 27;9:250. doi: 10.3389/fphar.2018.00250. eCollection 2018.
Danhong Injection (DHI) is widely used in clinics for treating cardiovascular and cerebrovascular diseases in China. However, the mode of action of DHI for neuroprotection remains unclear. In the present study, we deemed to investigate the effects of DHI on a rat model of cerebral ischemia/reperfusion injury (IRI) with an emphasis on its regulated gene profile obtained from microarray assays. Firstly, we showed that a 14-day DHI treatment effectively ameliorated severity of neurological deficits, reduced size of ischemic damage, improved status of oxidation stress, as well as systemic inflammation for IRI rats, along with which was a pronounced reduced cell infiltration in the area of periaqueductal gray matter. Secondly, bioinformatic analyses for the 429 differentially expressed genes (DEGs) regulated by DHI treatment pointed out ECM-receptor interaction, neuroactive ligand-receptor interaction, and endocytosis as the top three biological processes, while Toll-like recptor 4 (TLR4) as the most relavant singaling molecule. Lastly, we provided evidences showing that DHI might directly protect primary astrocytes from oxygen and glucose deprivation/re-oxygenation (OGD/Re) injury, the effects of which was associated with LAMC2 and ADRB3, two DEGs related to the top three biological processes according to transcriptomic analysis. In conlusion, we reported that DHI might work through maintaining the integrity for brain-blood barrier and to regulate TLR4-related signaling pathway to diminish the inflammation, therefore, effectively improved the outcomes of IRI. Our findings suggested that the attenuated astrocytic dysfunction could be a novel mechanism contributing to the neuroprotective effects of DHI against cerebral ischemia/reperfusion-induced damage.
丹红注射液(DHI)在中国临床上广泛用于治疗心脑血管疾病。然而,DHI的神经保护作用机制尚不清楚。在本研究中,我们旨在研究DHI对大鼠脑缺血/再灌注损伤(IRI)模型的影响,重点关注通过微阵列分析获得的其调控的基因谱。首先,我们发现为期14天的DHI治疗有效改善了IRI大鼠的神经功能缺损严重程度,减小了缺血损伤面积,改善了氧化应激状态以及全身炎症反应,同时导水管周围灰质区域的细胞浸润明显减少。其次,对DHI治疗调控的429个差异表达基因(DEG)进行生物信息学分析指出,细胞外基质-受体相互作用、神经活性配体-受体相互作用和内吞作用是排名前三的生物学过程,而Toll样受体4(TLR4)是最相关的信号分子。最后,我们提供的证据表明,DHI可能直接保护原代星形胶质细胞免受氧糖剥夺/复氧(OGD/Re)损伤,其作用与LAMC2和ADRB3有关,这两个DEG根据转录组分析与排名前三的生物学过程相关。总之,我们报道DHI可能通过维持血脑屏障的完整性和调节TLR4相关信号通路来减轻炎症,从而有效改善IRI的结局。我们的研究结果表明,星形胶质细胞功能障碍的减轻可能是DHI对脑缺血/再灌注诱导损伤具有神经保护作用的一种新机制。